Elapegademase

Last updated
Elapegademase
Clinical data
Trade names Revcovi
Other nameselapegademase-lvlr
AHFS/Drugs.com Monograph
License data
Routes of
administration 		Intramuscular
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG

Elapegademase, sold under the brand name Revcovi, is a medication for the treatment of the rare disease adenosine deaminase deficiency-SCID in children and adults. [1]

It is a recombinant enzyme [2] that is administered weekly by intramuscular injection. [3]

Elapegademase may interact with PEGylated drugs. [3]

Elapegademase-lvlr was approved by the U.S. Food and Drug Administration (FDA) in 2018. [4] [5] [6] Leadiant Biosciences was awarded a priority review voucher for its development under the pediatric rare diseases program. [7]

References

  1. ↑ Skidmore-Roth L (2022). "Elapegademase". Mosby's 2023 Nursing Drug Reference. Elsevier Health Sciences. p. 429. ISBN   978-0-323-93330-8.
  2. ↑ "Elapegademase: Drug Information" . www.uptodate.com. Retrieved 28 March 2019.
  3. 1 2 "LexiComp: Elapegademase-lvlr" . LexiComp. Retrieved 28 March 2019.
  4. ↑ "Drug Approval Package: Revcovi". U.S. Food and Drug Administration (FDA). 7 November 2018. Archived from the original on December 26, 2019. Retrieved 26 December 2019.
  5. ↑ "Elapegademase-lvlr Orphan Drug Designation and Approval". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 26 December 2019.
  6. ↑ "Drug Trial Snapshot: Revcovi". U.S. Food and Drug Administration (FDA). 5 October 2018. Retrieved 26 December 2019.
  7. ↑ "Elapegademase - Leadiant Biosciences" . AdisInsight. Springer Nature Switzerland AG. Retrieved 28 March 2019.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.